Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.33 -1.04 (-2.29%)

Streaming Delayed Price Updated: 3:01 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗

January 08, 2025

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

Via Investor's Business Daily

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

January 06, 2025

From Exelixis, Inc.

Via Business Wire

In the world of growth stocks, NASDAQ:EXEL shines as a value proposition. ↗

January 06, 2025

NASDAQ:EXEL is showing decent growth, but is still valued reasonably.

Via Chartmill

(EXEL) - Analyzing Exelixis's Short Interest ↗

January 06, 2025

Via Benzinga

Arcellx Stock Earns 82 Relative Strength Rating ↗

December 27, 2024

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Via Investor's Business Daily

Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents. ↗

December 20, 2024

EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Peering Into Exelixis's Recent Short Interest ↗

December 18, 2024

Via Benzinga

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts ↗

December 17, 2024

Via Benzinga

NASDAQ:EXEL is showing decent growth, but is still valued reasonably. ↗

December 16, 2024

EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.

Via Chartmill

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

December 17, 2024

Via Benzinga

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in December ↗

December 07, 2024

Via The Motley Fool

End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis) ↗

December 01, 2024

As the calendar winds down, the stock market often heats up. This

Via Talk Markets

Topics Stocks / Equities

Ten Young Ones ↗

November 30, 2024

Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays.

Via Talk Markets

Topics Stocks / Equities

Earnings Preview: Exelixis ↗

October 28, 2024

Via Benzinga

1 No-Brainer Stock to Buy With $40 ↗

October 23, 2024

The midcap biotech just became an even better buy.

Via The Motley Fool

NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗

November 29, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

November 27, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

November 26, 2024

From Exelixis, Inc.

Via Business Wire

BioNTech Stock Got A IBD RS Rating Lift ↗

November 14, 2024

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

Via Investor's Business Daily

Vericel Stock Sees RS Rating Shoot Higher ↗

November 11, 2024

The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.

Via Investor's Business Daily

NASDAQ:EXEL is an undervalued gem with solid fundamentals. ↗

November 08, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

November 07, 2024

From Exelixis, Inc.

Via Business Wire

3 Magnificent Stocks Under $100 to Buy in November ↗

November 03, 2024

The price could be right for these stocks.

Via The Motley Fool

Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗

November 03, 2024

The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts.

Via Benzinga

Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday ↗

October 30, 2024

Via Benzinga

Exelixis (EXEL) Q3 2024 Earnings Call Transcript ↗

October 30, 2024

EXEL earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

October 29, 2024

From Exelixis, Inc.

Via Business Wire

Biotech Momentum Trades For The Q4 Rally ↗

October 29, 2024

The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.

Via Talk Markets

Momentum Has Narrowed Again, Significantly ↗

October 28, 2024

It is more of a stock pickers market than usual as momentum factors are currently exaggerated.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.